A review of marketed drugs, novel pharmaceutical therapies, and natural products highlights emerging therapeutic targets and agents for the treatment of pulmonary arterial hypertension.
This review provides a comprehensive overview of current and emerging targeted therapies for pulmonary arterial hypertension, emphasizing the need for novel agents to improve long-term survival.
Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH remains a severe clinical condition, and the long-term survival of patients with PAH is still suboptimal. Thus, potential therapeutic targets and new agents to treat PAH are urgently needed. In recent years, a variety of related pathways and potential therapeutic targets have been found, which brings new hope for PAH therapy. In this perspective, not only are the marketed drugs used to treat PAH summarized but also the recently developed novel pharmaceutical therapies currently in clinical trials are discussed. Furthermore, the advances in natural products as potential treatment for PAH are also updated.
Zheng et al. (Mon,) conducted a review in Pulmonary arterial hypertension (PAH). Targeted drugs for PAH was evaluated. A review of marketed drugs, novel pharmaceutical therapies, and natural products highlights emerging therapeutic targets and agents for the treatment of pulmonary arterial hypertension.